A combination of two drugs commonly prescribed for enlarged prostate may be more effective than either of the medicines alone, according to a new study.
Enlarged prostate, also called benign prostatic hyperplasia (BPH), is a common urologic condition that affects about 50 percent of men between the ages of 51 and 60 and up to 90 percent of men over the age of 80.
The findings by researchers at UT Southwestern Medical Center compared treatments for three groups of study participants with enlarged prostates over four years.
The study, which included more than 4,800 men, is one of the first to compare single and combo medication regimens in such a large group.
The first group of study participants received the drug dutasteride; the second group received tamsulosin; and the third received a combination of the two medicines.
"We found the combination therapy to be superior at reducing risk of BPH progression," said Dr. Claus Roehrborn, chairman of urology at UT Southwestern and lead author of the study.
"The two medications joined forces in terms of symptom control. On the strengths of both dutasteride and tamsulosin, participants reported fewer symptoms, and we observed a 25 percent reduction in prostate volume," Roehrborn added.
Dr. Roehrborn added that subjects who received the combination therapy also showed a 50 percent reduction of prostate-specific antigen (PSA), a protein produced by both cancerous and noncancerous prostate tissue.
The study has been published in a recent issue of the journal European Urology. (ANI)